Slide 1: 2020 Full Year Financial Results
2020 FULL YEAR FINANCIAL RESULTS MARCH 22, 2021
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Highlights FY 2020
3 FY Financial Results HIGHLIGHTS FY 2020 +5% +37% €19,4 +22% Mio EBITDA NET RESTATED RESULT NET REVENUES € 56,4 M POSITIVE NET FINANCIAL POSITION RESTATED € 11,6 M (+5% COMPARE TO FY 2019) +5,8M COMPARED TO FY 2019 € 16,0M (+37% COMPARED TO FY 2019) (+22% COMPARED TO FY 2019)
Slide 4: Economic Results
4 FY Financial Results ECONOMIC RESULTS EBITDA Restated and Net Result Restated on Net Revenues 2020 Ebitda restated shows a higher marginality% compared to 2019 due to lower operating costs caused by the covid-19 restrictions (commercial and marketing) 2020 Net Result Restated benefits from the tax
Slide 5: Profit and Loss
5 FY Financial Results Profit and Loss 2020 Net Revenues have been affected from the Covid-19 Management 2020 PROFIT AND LOSS (€/000) 2020 2019 pandemic in terms of lower increase in comparison with previous Adj. RESTATED years. A) REVENUES 58.680 (1.049) 57.631 54.214 Other revenues include an amou
Slide 6: Net Revenues
6 FY Financial Results NET REVENUES
Slide 7: Net Revenues: Breakdown by Area of Business and Geographic Area
7 FY Financial Results NET REVENUES Breakdown by Area of Business Breakdown by geographic Area Far East Other Middle East 2% countries 11% 1% Europe 16% Italy 71% Breakdown by area Incidence % Revenues Breakdown by geographic area Incidence % €/1000 2020 2019 Δ% 2020 2019 €/1000 2020 2019 Δ% 2020 20
Slide 8: Net Revenues: Breakdown by Trademark
8 FY Financial Results NET REVENUES Breakdown by Trademark F.P. revenues breakdown by Trademark Incidence % €/1000 2020 2019 Δ% 2020 2019 Sideral 43.603 40.463 7,8% 81% 78% Cetilar 5.512 5.389 2,3% 10% 10% Apportal 2.391 1.927 24,1% 4% 4% Ultramag 558 869 -35,8% 1% 2% Others Trademark 2.041 2.920 -3
Slide 9: Consolidated Balance Sheet
9 FY Financial Results CONSOLIDATED BALANCE SHEET Amounts in €/000 31/12/2020 31/12/2019 Trade Payables Trade receivables 15.053 15.028 Reduction due to lower operating expenses Inventories 1.894 1.853 Other Receivables Trade Payables (7.175) (8.165) Increase due to tax receivables (Patent Box refer
Slide 10: Consolidated Cash Flow
10 FY Financial Results CONSOLIDATED CASH FLOW Cash Flow (€/1000) 31/12/2020 31/12/2019 Net result 14.072 8.454 Amortization, depreciation & write off NON MONETARY EXPENSES Write off of the indeminity related to the non renewal Amortization, depreciation and w.o. 2.338 973 of a distribution agreemen
Slide 11: Net Financial Position Evolution
11 FY Financial Results NET FINANCIAL POSITION EVOLUTION PFN The Net Financial Position at 31.12.2020 is € 19,359 with an improvement of € 5,799. The cash flow from operating activities contributes € 11,795 to the improvement of the NFP.
Slide 12: Units Sold
12 FY Financial Results UNITS SOLD
Slide 13: Outlook 2021
OUTLOOK 2021
Slide 14: Outlook 2021
14 / Outlook 2021 OUTLOOK 2021 • The outlook for 2021 is positive; strategies implemented in 2020 following the changed operating conditions due to Covid-19, which were focused on strengthening and protecting the business, put the Group in a position to effectively manage the current moment taking a
Slide 15: Slide 15